BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Scribano ML. Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence. World J Gastroenterol 2018; 24(23): 2457-2467 [PMID: 29930467 DOI: 10.3748/wjg.v24.i23.2457]
URL: https://www.wjgnet.com/1007-9327/full/v24/i23/2457.htm
Number Citing Articles
1
Tamar Getter, Raanan Margalit, Shirin Kahremany, Laura Levy, Eliav Blum, Netaly Khazanov, Nimrod Y. Keshet-Levy, Tigist Y. Tamir, M. Ben Major, Ron Lahav, Sofia Zilber, Hanoch Senderowitz, Paul Bradfield, Beat A. Imhof, Evgenia Alpert, Arie Gruzman. Novel inhibitors of leukocyte transendothelial migrationBioorganic Chemistry 2019; 92: 103250 doi: 10.1016/j.bioorg.2019.103250
2
Lorenzo Bertani, Laura Baglietto, Luca Antonioli, Matteo Fornai, Gherardo Tapete, Eleonora Albano, Linda Ceccarelli, Maria Gloria Mumolo, Carolina Pellegrini, Ersilia Lucenteforte, Nicola Bortoli, Massimo Bellini, Santino Marchi, Corrado Blandizzi, Francesco Costa. Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patientsBritish Journal of Clinical Pharmacology 2020; 86(7): 1296 doi: 10.1111/bcp.14235
3
Chathyan Pararasa, Na Zhang, Thomas J. Tull, Ming H. A. Chong, Jacqueline H. Y. Siu, William Guesdon, Konstantia Maria Chavele, Jeremy D. Sanderson, Louise Langmead, Klaartje Kok, Jo Spencer, Anna Vossenkamper. Reduced CD27−IgD− B Cells in Blood and Raised CD27−IgD− B Cells in Gut-Associated Lymphoid Tissue in Inflammatory Bowel DiseaseFrontiers in Immunology 2019; 10 doi: 10.3389/fimmu.2019.00361
4
Andrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, Jean-Frederic Colombel, Jyoti Chauhan, Marion Ehrich, Nicholas Farinola, Josep Bassaganya-Riera. The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical TrialInflammatory Bowel Diseases 2019;  doi: 10.1093/ibd/izz094
5
Beatriz Chaves, Geraldo R. Sartori, Disraeli C. A. Vasconcelos, Wilson Savino, Ernesto R. Caffarena, Vinícius Cotta-de-Almeida, João H. M. da Silva. Guidelines To Predict Binding Poses of Antibody–Integrin ComplexesACS Omega 2020; 5(27): 16379 doi: 10.1021/acsomega.0c00226
6
L.V. Tarasova, E.I. Busalaeva, Yu.V. Tsyganova, N.V. Zhudtlina, I.D. Matysyakevich. Vedolizumab in ulcerative colitis: clinical caseDokazatel'naya gastroenterologiya 2020; 9(3): 77 doi: 10.17116/dokgastro2020903177
7
Caroline Di Jiang, Tim Raine. IBD considerations in spondyloarthritisTherapeutic Advances in Musculoskeletal Disease 2020; 12: 1759720X2093941 doi: 10.1177/1759720X20939410
8
Marco Zuani, Chiara Secco, Barbara Frossi. Mast cells at the crossroads of microbiota and IBDEuropean Journal of Immunology 2018; 48(12): 1929 doi: 10.1002/eji.201847504
9
Thomas X. Lu, Russell D. Cohen. Maneuvering Clinical Pathways for Crohn’s DiseaseCurrent Gastroenterology Reports 2019; 21(5) doi: 10.1007/s11894-019-0687-4
10
Yunwei Wang, Jennifer Wang, Joel Pekow, Sushila Dalal, Russell D Cohen, Jacob Ollech, Amanda Israel, Benjamin D Shogan, Dejan Micic, Lisa Cannon, Konstantin Umanskiy, Roger Hurst, Neil Hyman, David T Rubin, Atsushi Sakuraba. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist‐maintained clinical remissionJournal of Gastroenterology and Hepatology 2019; 34(12): 2090 doi: 10.1111/jgh.14751
11
Kevin Groudan, Kamesh Gupta, Rohit Singhania. Vedolizumab (Entyvio®) for the Treatment of Pyoderma Gangrenosum in a Crohn’s Disease PatientCureus 2021;  doi: 10.7759/cureus.12582
12
Ugo Cucinotta, Valeria Dipasquale, Stefano Costa, Salvatore Pellegrino, Vincenzo Ramistella, Claudio Romano. Vedolizumab‐associated pulmonary manifestations in children with ulcerative colitisJournal of Clinical Pharmacy and Therapeutics 2021;  doi: 10.1111/jcpt.13494
13
Thomas Klag, Jan Wehkamp, Eduard Stange. Wirkmechanismen und Wirkung von Biologika und JAK-Inhibitoren bei CEDGastro-News 2019; 6(1): 26 doi: 10.1007/s15036-019-0482-y
14
Ralley E. Prentice, Clarissa Rentsch, Aysha H. Al‐Ani, Eva Zhang, Douglas Johnson, John Halliday, Robert Bryant, Jacob Begun, Mark G. Ward, Peter J. Lewindon, Susan J. Connor, Simon Ghaly, Britt Christensen. SARS‐CoV‐2 vaccination in patients with inflammatory bowel diseaseGastroHep 2021; 3(4): 212 doi: 10.1002/ygh2.473
15
Gerhard Rogler. Mechanism of action of vedolizumab: do we really understand it?Gut 2019; 68(1): 4 doi: 10.1136/gutjnl-2018-316777
16
Daxin Guo, Ke Jiang, Jiaze Hong, Mengting Zhang, Yetan Shi, Bin Zhou. Association between vedolizumab and postoperative complications in IBD: a systematic review and meta-analysisInternational Journal of Colorectal Disease 2021; 36(10): 2081 doi: 10.1007/s00384-021-04017-2
17
Virginia Solitano, Gionata Fiorino, Ferdinando D’Amico, Laurent Peyrin-Biroulet, Silvio Danese. Thrombosis in IBD in the Era of JAK InhibitionCurrent Drug Targets 2020; 22(1): 126 doi: 10.2174/1389450121666200902164240
18
Renu Bhandari, Opemipo D Ogeyingbo, Roaa Kareem, Mallika Gyawali, Nanditha Venkatesan, Rowan Ahmed, Rinky A Botleroo, Abeer O Elshaikh. Efficacy and Safety of Vedolizumab in Management of Moderate to Severe Ulcerative Colitis: A Systematic ReviewCureus 2021;  doi: 10.7759/cureus.17729
19
Thomas Wilke, Antje Groth, Gráinne H. Long, Amanda R. Tatro, Diana Sun. Rate of Adverse Events and Associated Health Care Costs for the Management of Inflammatory Bowel Disease in GermanyClinical Therapeutics 2020; 42(1): 130 doi: 10.1016/j.clinthera.2019.11.012
20
S. Hopkin, J.M. Lord, M. Chimen. Dysregulation of leukocyte trafficking in ageing: Causal factors and possible corrective therapiesPharmacological Research 2021; 163: 105323 doi: 10.1016/j.phrs.2020.105323
21
Hiroshi Nakase. 4) Treatment of Inflammatory Bowel Disease Based on the Pathophysiology-for the Present and the Future-Nihon Naika Gakkai Zasshi 2020; 109(9): 1759 doi: 10.2169/naika.109.1759
22
Karma Yeshi, Roland Ruscher, Luke Hunter, Norelle L. Daly, Alex Loukas, Phurpa Wangchuk. Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural ProductsJournal of Clinical Medicine 2020; 9(5): 1273 doi: 10.3390/jcm9051273
23
Giorgos Bamias, Georgios Kokkotis, Michalis Gizis, Christina Kapizioni, Konstantinos Karmiris, Evgenia Koureta, Nikolaos Kyriakos, Georgios Leonidakis, Konstantinos Makris, Panagiotis Markopoulos, Georgios Michalopoulos, Spyridon Michopoulos, Ioannis Papaconstantinou, Dimitrios Polymeros, Spyros I. Siakavellas, Konstantinos Triantafyllou, Eftychia Tsironi, Emmanouela Tsoukali, Maria Tzouvala, Nikos Viazis, Vassileios Xourafas, Eirini Zacharopoulou, Evanthia Zampeli, Konstantinos Zografos, George Papatheodoridis, Gerasimos Mantzaris. Predictors of Response to Vedolizumab in Patients with Ulcerative Colitis: Results from the Greek VEDO-IBD CohortDigestive Diseases and Sciences 2021;  doi: 10.1007/s10620-021-06907-5
24
Lorenzo Bertani, Gian Paolo Caviglia, Luca Antonioli, Rinaldo Pellicano, Sharmila Fagoonee, Marco Astegiano, Giorgio Maria Saracco, Elisabetta Bugianesi, Corrado Blandizzi, Francesco Costa, Davide Giuseppe Ribaldone. Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel DiseasesJournal of Clinical Medicine 2020; 9(5): 1323 doi: 10.3390/jcm9051323
25
Hiroshi Nakase. Treatment of inflammatory bowel disease from the immunological perspectiveImmunological Medicine 2020; 43(2): 79 doi: 10.1080/25785826.2020.1751934
26
Amandip Kaur, Paraskevi Goggolidou. Ulcerative colitis: understanding its cellular pathology could provide insights into novel therapiesJournal of Inflammation 2020; 17(1) doi: 10.1186/s12950-020-00246-4
27
Georgia Kyriakou, Maria Gkermpesi, Konstantinos Thomopoulos, Markos Marangos, Sophia Georgiou. Metastatic vulvar Crohn’s disease preceding intestinal manifestations: a case report and short reviewActa Dermatovenerologica Alpina Pannonica et Adriatica 2019; 28(3) doi: 10.15570/actaapa.2019.32
28
Cath Stansfield. Vedolizumab (Entyvio) in Crohn's diseaseGastrointestinal Nursing 2021; 19(6): 20 doi: 10.12968/gasn.2021.19.6.20
29
Ida Schoultz, Åsa Keita. Cellular and Molecular Therapeutic Targets in Inflammatory Bowel Disease—Focusing on Intestinal Barrier FunctionCells 2019; 8(2): 193 doi: 10.3390/cells8020193
30
C. Abreu, R. Filipe, S. Lopes, A. Sarmento. Varicella under vedolizumab: Should we wait for the disease or propose the vaccine?Journal of Clinical Virology 2020; 126: 104333 doi: 10.1016/j.jcv.2020.104333
31
Lorenzo Bertani, Corrado Blandizzi, Maria Gloria Mumolo, Linda Ceccarelli, Eleonora Albano, Gherardo Tapete, Giovanni Baiano Svizzero, Federico Zanzi, Francesca Coppini, Nicola de Bortoli, Massimo Bellini, Riccardo Morganti, Santino Marchi, Francesco Costa. Fecal Calprotectin Predicts Mucosal Healing in Patients With Ulcerative Colitis Treated With Biological Therapies: A Prospective StudyClinical and Translational Gastroenterology 2020; 11(5): e00174 doi: 10.14309/ctg.0000000000000174
32
Fabiana Zingone, Brigida Barberio, Federico Compostella, Giulia Girardin, Renata D’Incà, Carla Marinelli, Ilaria Marsilio, Greta Lorenzon, Edoardo Vincenzo Savarino. Good efficacy and safety of vedolizumab in Crohn’s disease and ulcerative colitis in a real-world scenarioTherapeutic Advances in Gastroenterology 2020; 13: 175628482093653 doi: 10.1177/1756284820936536
33
George Hajishengallis, Triantafyllos Chavakis. Local and systemic mechanisms linking periodontal disease and inflammatory comorbiditiesNature Reviews Immunology 2021; 21(7): 426 doi: 10.1038/s41577-020-00488-6
34
Mario Fernández-Ruiz, José María Aguado. Direct T-cell Inhibition and Agents Targeting T-cell Migration and ChemotaxisInfectious Disease Clinics of North America 2020; 34(2): 191 doi: 10.1016/j.idc.2020.02.002
35
Hiroshi Nakase. The Leading Edge of the Treatment of Inflammatory Bowel DiseaseNihon Naika Gakkai Zasshi 2020; 109(6): 1145 doi: 10.2169/naika.109.1145
36
Patrick F van Rheenen, Marina Aloi, Amit Assa, Jiri Bronsky, Johanna C Escher, Ulrika L Fagerberg, Marco Gasparetto, Konstantinos Gerasimidis, Anne Griffiths, Paul Henderson, Sibylle Koletzko, Kaija-Leena Kolho, Arie Levine, Johan van Limbergen, Francisco Javier Martin de Carpi, Víctor Manuel Navas-López, Salvatore Oliva, Lissy de Ridder, Richard K Russell, Dror Shouval, Antonino Spinelli, Dan Turner, David Wilson, Eytan Wine, Frank M Ruemmele. The Medical Management of Paediatric Crohn’s Disease: an ECCO-ESPGHAN Guideline UpdateJournal of Crohn's and Colitis 2021; 15(2): 171 doi: 10.1093/ecco-jcc/jjaa161
37
Walter Reinisch, Krisztina Gecse, Jonas Halfvarson, Peter M Irving, Jørgen Jahnsen, Laurent Peyrin-Biroulet, Gerhard Rogler, Stefan Schreiber, Silvio Danese. Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s DiseaseInflammatory Bowel Diseases 2021; 27(1): 106 doi: 10.1093/ibd/izaa078
38
Sebastián Eduardo Ibáñez Vodnizza, María Paz Poblete De La Fuente, Elisa Catalina Parra Cancino. Approach to the Patient with Axial Spondyloarthritis and Suspected Inflammatory Bowel DiseaseRheumatic Disease Clinics of North America 2020; 46(2): 275 doi: 10.1016/j.rdc.2020.01.004
39
Amanda Nash, Samira Aghlara-Fotovat, Andrea Hernandez, Christopher Scull, Omid Veiseh. Clinical translation of immunomodulatory therapeuticsAdvanced Drug Delivery Reviews 2021; 176: 113896 doi: 10.1016/j.addr.2021.113896